Tigatuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | TNFRSF10B (TRAIL-R2) |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
918127-53-4  |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6406H9924N1716O2012S46 |
| Molar mass | 144.6 kg/mol |
 (what is this?) (verify) | |
Tigatuzumab (CS-1008) is a monoclonal antibody[1] for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed,[2] Phase II trials for colorectal cancer[3] and non-small cell lung cancer[4] are running, and a study for ovarian cancer has been approved.[5]
The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.[6]
A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.[7]
References
- ↑ WHO Drug Information
- ↑ NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
- ↑ NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
- ↑ NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
- ↑ NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
- ↑ NCI: CS-1008
- ↑ http://clincancerres.aacrjournals.org/content/early/2013/09/17/1078-0432.CCR-12-3104.abstract